Physician profile
Michael P Vik
NPI 1528061884
$1,322.91
in general payments reported to CMS, 2019-2025
24 companies · $531 in 2025
The $531 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.29 · 2020: $169 · 2021: $162 · 2022: $62.95 · 2023: $87.93 · 2024: $225 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $146.98 | 2025 | Korlym |
| Eisai INC. | $141.33 | 2020-2021 | |
| Inspire Medical Systems, INC. | $139.32 | 2024 | Inspire |
| Bausch Health US, LLC | $125.73 | 2019-2021 | |
| Exact Sciences Corporation | $115.46 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $89.64 | 2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $58.56 | 2023-2024 | Quviviq |
| Dexcom, INC. | $51.98 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $46.19 | 2021-2022 | |
| Lilly USA, LLC | $43.83 | 2024-2025 | Mounjaro, Zepbound |
| Heartflow, INC. | $42.98 | 2025 | |
| Romark Laboratories, Lc | $39.10 | 2019 | |
| Shield Therapeutics INC | $35.48 | 2025 | |
| Tms Neurohealth Centers INC. | $34.12 | 2025 | Tms Neurohealth Centers INC. |
| Supernus Pharmaceuticals, INC. | $33.60 | 2022-2023 | Xyosted, Tlando, Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $28.84 | 2021 | |
| Halozyme INC | $24.46 | 2023 | |
| Acella Pharmaceuticals, LLC | $24.27 | 2025 | NP Thyroid 60 |
| Ironshore Pharmaceuticals INC. | $22.05 | 2019 | |
| Antares Pharma, INC. | $22.03 | 2020 | |
| Pfizer INC. | $17.83 | 2024 | |
| Currax Pharmaceuticals LLC | $15.02 | 2022 | |
| Merck Sharp & Dohme LLC | $12.72 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.